154 related articles for article (PubMed ID: 12124839)
1. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.
Bukowski RM; Tendler C; Cutler D; Rose E; Laughlin MM; Statkevich P
Cancer; 2002 Jul; 95(2):389-96. PubMed ID: 12124839
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles FJ; Faderl S; Kantarjian HM
Blood; 2001 Sep; 98(6):1708-13. PubMed ID: 11535501
[TBL] [Abstract][Full Text] [Related]
6. Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia.
Gupta S; Jen J; Kolz K; Cutler D
Br J Clin Pharmacol; 2007 Mar; 63(3):292-9. PubMed ID: 16939523
[TBL] [Abstract][Full Text] [Related]
7. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
8. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.
Michallet M; Maloisel F; Delain M; Hellmann A; Rosas A; Silver RT; Tendler C;
Leukemia; 2004 Feb; 18(2):309-15. PubMed ID: 14671645
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
[TBL] [Abstract][Full Text] [Related]
10. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Jabbour E; Kantarjian H; Cortes J; Thomas D; Garcia-Manero G; Ferrajoli A; Faderl S; Richie MA; Beran M; Giles F; Verstovsek S
Cancer; 2007 Nov; 110(9):2012-8. PubMed ID: 17849460
[TBL] [Abstract][Full Text] [Related]
11. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.
Gupta SK; Swan SK; Marbury T; Smith W; Schwartz S; Kolz K; Cutler DL
Br J Clin Pharmacol; 2007 Dec; 64(6):726-32. PubMed ID: 17555463
[TBL] [Abstract][Full Text] [Related]
13. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
15. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of pegylated interferons in metastatic renal cell carcinoma.
Choueiri TK; Hutson TE; Bukowski RM
Expert Rev Anticancer Ther; 2003 Dec; 3(6):823-9. PubMed ID: 14686704
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
20. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
